Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14552MR)

This product GTTS-WQ14552MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14552MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8536MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ5029MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ11346MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ12632MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ4164MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ8106MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ4848MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ13055MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW